Pulmatrix, Inc.

Start Phase 1/Phase 2 clinical study of PUR3100 after IND-enabling toxicology

Deadline passed; outcome being checked

Announced: 4 Mar 2021
Due: 31 Mar 2022
Status: Checking

Deadline
Met
Late
Not met
Today

What the company said

“PUR3100 plans to advance into IND enabling toxicology studies with anticipated Ph1/Ph2 clinical study start in Q1 2022.”

SourcePulmatrix, Inc. Form 8-K press release, 2021-03-04
FilingSEC filing index
Deadline as statedin Q1 2022
Deadline used31 Mar 2022, the last day of the stated period
TypeProject
Permanent referenceKI-C-2021-PULM-025184
Cite as https://keptindex.org/c/KI-C-2021-PULM-025184/ — this address never changes.

What we found

The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical milestone
Indicative materiality: Medium rules
Action: Start
Deliverable: PUR3100 Phase 1/Phase 2 clinical study
Language: Expected (“expects”, “plans”)
In the company’s control: Medium
Specificity: High
Conditional: Yes: completion of IND-enabling toxicology studies
Depends on: Regulatory

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Pulmatrix, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-PULM-025184 · Corrections policy